-transparent.png){kind=logo}
This case is a 71-year-old female. As hormonotherapy, 400 mg/day of MPA alone was orally administered in a lung metastatic case of cancer of the uterine body in the IV stage. Although progressing for 2 years and 1 month after the initial administration, lung metastatic foci disappeared, and recurrence was not noted, and serious side effect by using MPA was also not noted. Progesterone therapy such this case is considered as one of therapeutic methods which can be expected remarkably effective rate in the lu metastatic foci of cancer of the uterine body.
Related Publications
M Takeda, and
K Kubo, and
M Fukushima, and
J Hirayama, and
M Sekiguchi
April 1996,
Gan to kagaku ryoho. Cancer & chemotherapy,
M Takeda, and
K Kubo, and
M Fukushima, and
J Hirayama, and
M Sekiguchi
October 1994,
Gan to kagaku ryoho. Cancer & chemotherapy,
M Takeda, and
K Kubo, and
M Fukushima, and
J Hirayama, and
M Sekiguchi
August 1987,
Gan to kagaku ryoho. Cancer & chemotherapy,
M Takeda, and
K Kubo, and
M Fukushima, and
J Hirayama, and
M Sekiguchi
January 1993,
European journal of cancer (Oxford, England : 1990),
M Takeda, and
K Kubo, and
M Fukushima, and
J Hirayama, and
M Sekiguchi
July 2003,
Gan to kagaku ryoho. Cancer & chemotherapy,
M Takeda, and
K Kubo, and
M Fukushima, and
J Hirayama, and
M Sekiguchi
January 1995,
Gan to kagaku ryoho. Cancer & chemotherapy,
M Takeda, and
K Kubo, and
M Fukushima, and
J Hirayama, and
M Sekiguchi
October 1979,
Tumori,
M Takeda, and
K Kubo, and
M Fukushima, and
J Hirayama, and
M Sekiguchi
January 1994,
Cancer chemotherapy and pharmacology,
M Takeda, and
K Kubo, and
M Fukushima, and
J Hirayama, and
M Sekiguchi
October 1977,
Psychoneuroendocrinology,
M Takeda, and
K Kubo, and
M Fukushima, and
J Hirayama, and
M Sekiguchi
May 1993,
British journal of cancer,
